BBA
VERA icon

Baker Bros. Advisors’s Vera Therapeutics VERA Stock Holding History

Baker Bros. Advisors’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-146,464
Closed -$2.35M – 109
2023
Q2 		$2.35M Sell
146,464
-186,869
-56% -$1.69M 0.01% 92
2023
Q1 		$2.59M Hold
333,333
– – 0.01% 85
2022
Q4 		$6.45M Hold
333,333
– – 0.04% 71
2022
Q3 		$7.1M Hold
333,333
– – 0.05% 68
2022
Q2 		$4.54M Hold
333,333
– – 0.03% 81
2022
Q1 		$7.83M Buy
+333,333
New +$7.17M 0.05% 72

Other funds holding VERA

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Baker Bros. Advisors's VERA Position: Q3 2023 in Review

Baker Bros. Advisors sold out of Vera Therapeutics (VERA) in Q3 2023, closing a stake of 146,464 shares — an estimated $2.35M sold.

Baker Bros. Advisors first reported a position in VERA in Q1 2022 and held it in 6 quarters. The position peaked at $7.83M in Q1 2022. 84 funds tracked by Wall St. Rank hold VERA as of Q3 2023.

  • Baker Bros. Advisors reported no remaining Vera Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 146,464 Vera Therapeutics shares in Q3 2023, an estimated $2.35M.
  • Baker Bros. Advisors first reported a position in Vera Therapeutics in Q1 2022 and held it in 6 quarters.
  • Baker Bros. Advisors's Vera Therapeutics position peaked at $7.83M in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2023.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.